This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

2014 FDA Drug Approval Calendar

NEW YORK (TheStreet) -- It's been awhile since I updated the FDA drug approval calendar. Here's the latest list of drugs under FDA review. Included as well are relevant FDA advisory panel dates. 

Enjoy.

May 2014:

Biogen Idec  (BIIB)
Plegridy for multiple sclerosis
May 21

Eli Lilly  (LLY)and Dyax (DYAX)
Ramucirumab for gastric cancer
May 23

Durata Therapeutics (DRTX) 
Dalbavancin for skin infections
May 26
(An FDA advisory panel in March voted to recommend approval.)

Omeros (OMER - Get Report)
OMS302 for ocular inflammation
May 30


June 2014: 

BioDelivery Sciences  (BDSI - Get Report)
Bunavail for opioid addiction
June 6

Exact Sciences (EXAS)
Cologuard for colon cancer screening
June 6 

Keryx Pharmaceuticals  (KERX - Get Report)
Zerenex for hyperphosphatemia (kidney dialysis)
June 6

Orexigen Therapeutics (OREX - Get Report)
Contrave for obesity
June 10 

June 11-12
FDA advisory committee meeting to discuss treatments for opioid-induced constipation
AstraZeneca (AZN) and Nektar Therapeutics (NKTR) - naloxogel
Salix Pharma (SLXP) -- Relistor

Biogen Idec 
Eloctate for hemophilia A
June 12

Cubist Pharma  (CBST)
Tedizolid for skin infections
June 20

July 2014: 

MannKind  (MNKD)
Afrezza for diabetes
July 15

July 24
FDA advisory panel
NPS Pharmaceuticals (NPSP)
Natpara for hypoparathyroidism July 24

Anacor Pharma
  (ANAC)
Tavaborole for toe fungus
July 29


August 2014: 

Medicines Co. (MDCO)
Oritavancin for skin infections (MRSA)
Aug. 6

Spectrum Pharmaceuticals (SPPI)
Belinostat for peripheral T-cell lymphoma
Aug. 8

Regeneron Pharmaceuticals (REGN)
Eylea for diabetic macular edema (expansion of label)
Aug. 18


September 2014: 

Gilead Sciences (GILD)
Idelalisib for indolent non-Hodgkin's lymphoma 
Sept. 11 (pending FDA acceptance of priority review)

AstraZeneca and Nektar Therapeutics
Naloxegol for opioid-induced constipation
Sept. 16

Celgene (CELG)
Otezla for psoriasis (expansion of label)
Sept. 23


October 2014: 

NPS Pharmaceuticals  (NPSP)
Natpara for hypoparathyroidism
Oct. 24

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
NPSP $45.97 0.02%
BDSI $8.22 0.00%
KERX $10.90 0.00%
OREX $6.67 0.00%
OMER $20.43 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs